Workup for Subclinical Hyperthyroidism (TSH 0.02 with Normal T4/T3)
You should first repeat the TSH measurement within 4 weeks along with confirmatory free T4 and free T3 levels, then proceed with radioactive iodine uptake and scan to determine the underlying etiology. 1
Initial Confirmation Step
With a TSH of 0.02 mIU/L (below 0.1), this represents subclinical hyperthyroidism that requires systematic evaluation. The first critical step is confirmation through repeat testing because TSH can be transiently suppressed by various factors 1.
- Timing of repeat labs: Within 4 weeks for TSH <0.1 mIU/L 1
- If the patient has cardiac disease, atrial fibrillation, or other serious conditions, repeat within 2 weeks
- Measure TSH, free T4, AND total T3 or free T3 simultaneously
This repeat testing serves two purposes: confirming persistent suppression and excluding T3 toxicosis (where only T3 is elevated while T4 remains normal) 2.
Determining the Etiology
Once you've confirmed persistent TSH suppression with normal thyroid hormones, the next essential test is radioactive iodine uptake (RAIU) and thyroid scan 2. This distinguishes between:
High/Normal Uptake Conditions:
- Graves' disease (diffuse uptake pattern)
- Toxic adenoma or toxic multinodular goiter (focal/patchy uptake)
- TSH-secreting pituitary adenoma (rare)
Low/Absent Uptake Conditions:
- Painless (silent) thyroiditis
- Subacute thyroiditis
- Exogenous thyroid hormone intake
- Amiodarone-induced thyroiditis
Clinical Context Matters
Assess for high-risk features that influence urgency and treatment decisions:
- Cardiac risk factors: Age >65, history of atrial fibrillation, heart disease, or arrhythmias 1
- Bone health: Postmenopausal women are at increased risk for bone loss and fractures with persistent TSH suppression 1
- Medication history: Review for levothyroxine use (exogenous subclinical hyperthyroidism) or recent iodine exposure
The guidelines emphasize that patients with nodular thyroid disease on physical exam are particularly likely to have underlying autonomous thyroid function 3. In one study, all ambulatory patients with suppressed TSH and normal thyroid hormones had either multinodular glands or solitary nodules 4.
Additional Considerations
If the RAIU/scan shows nodular disease, thyroid ultrasound provides anatomic detail about nodule size and characteristics that may influence treatment decisions.
If clinical presentation is atypical (e.g., young patient without palpable thyroid abnormality), consider:
- TSH receptor antibodies (TRAb) to evaluate for Graves' disease
- Thyroid peroxidase antibodies (TPO) if autoimmune thyroiditis is suspected
Common Pitfalls to Avoid
- Don't assume transient suppression: Up to 47% of patients with low but detectable TSH will normalize spontaneously, but those with TSH <0.1 are more likely to have true pathology 5
- Don't skip the repeat testing: Single measurements can be misleading due to assay variability, non-thyroidal illness, or medication effects 1
- Don't forget T3 measurement: Approximately 0.5% of cases represent isolated T3 toxicosis that would be missed without measuring T3 6, 4
The structured approach of confirm → localize → risk-stratify ensures you identify the underlying cause while avoiding unnecessary treatment of transient TSH suppression 1, 2.